Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Featured Article from MarketBeat.com Global Medical: This REIT Just Got a 30% Price TargetWritten by Sam Quirke. Published 10/20/2025. 
Key Points - Global Medical REIT’s multi-year downtrend may finally be ending.
- Fresh analyst upgrades are indicating as much as a nearly 30% upside from current levels.
- A juicy 9.3% dividend yield adds to an increasingly attractive risk/reward setup.
Real Estate Investment Trusts, or REITs, are often a favorite among income investors. They offer regular dividends, provide exposure to tangible assets, and can serve as a natural hedge against inflation. Within that universe, Global Medical REIT Inc. (NYSE: GMRE) stands out as a niche player focused on healthcare properties. Its portfolio includes medical office buildings, outpatient facilities, and specialty care centers—all backed by long-term leases and stable tenants. Frustratingly for investors, however, while this brick-and-mortar stability looks good on paper, it hasn't helped Global Medical much in recent years. Its shares have been in a persistent decline since December 2021, losing more than 60% of their value. As we'll see below, several factors contributed to the drop, and the stock hit fresh all-time lows earlier this month. Decades of chemical pesticide use have left behind a toxic legacy. But a safer alternative is gaining ground – and Med-X is leading the charge.
This is no longer just a niche preference – it's a macro shift. Consumers, businesses, and regulators are demanding cleaner options. That's why Med-X has made it their mission to meet the market where it's going, not where it's been. Learn more about Med-X's investment opportunity But after years of relentless selling, there are finally signs of a bottom forming. With several analysts starting to turn bullish and the technical picture improving, there are reasons to think that Global Medical's long-awaited recovery is beginning to take shape. Let's jump in and take a closer look. A Brutal Downtrend, But a Clear Floor Emerging Much of the stock's decline can be attributed to higher interest rates and investor skepticism toward debt-heavy real estate names, which made the bears particularly focused on Global Medical. Management's decision to trim the dividend by 29% earlier this year also shook investor confidence during a period of consolidation. Still, the stock may have found a floor. The $30 level has emerged as a meaningful line of support — it's where the bears ran out of steam last May, and buyers have been stepping in again. Over the past week, shares have bounced sharply off the $30 level, suggesting that larger funds might be quietly building positions. Momentum indicators are also starting to favor the bulls. The RSI has rebounded from deeply oversold territory, and the stock's MACD is on the verge of a bullish crossover. After nearly four years of downward pressure, Global Medical's chart shows early signs of putting in a low, which makes it an interesting entry point for sidelined investors. Analysts Are Turning Bullish Again An ongoing shift in Wall Street sentiment is reinforcing that case. Earlier this week, Citizens JMP upgraded its rating on Global Medical from Market Perform to Outperform and set a new price target of $40. From where the stock closed on Wednesday evening, that implies upside of nearly 30%. That bullish view echoed Zacks Research, which upgraded Global Medical to Strong Buy last month, highlighting growing optimism across the analyst community. There appears to be increasing confidence that much of the downside has been priced in, while an improving balance sheet and a supportive macro backdrop are additional positives. Indeed, the broader environment for REITs is starting to improve. Expectations of further interest-rate cuts would benefit yield-sensitive names like Global Medical, and the company's recently announced $50 million share repurchase program adds another layer of support. The new CEO's focus on deleveraging signals that management is intent on turning the page after a difficult few years for shareholders. For investors considering entry around the $30 mark, the company's 9.31% dividend yield is particularly compelling. It provides an attractive income stream even if the recovery takes time. Risks Remain, But The Setup Is Compelling That said, risks persist. Global Medical remains highly sensitive to interest-rate movements, and while the Fed appears to be in a softening cycle, the timing of rate cuts is uncertain. The company also faces lingering skepticism from investors who watched the shares continue to sell off while the broader market pushed to new highs this past summer. Still, the risk/reward balance looks favorable at current levels. After a roughly 60% peak-to-trough decline, much of the negative news appears priced in, and recent analyst upgrades suggest sentiment is beginning to shift. If shares can hold above $30 through the rest of October, it would help confirm that a durable base has formed. From there, the technical setup and analyst targets point to room for a meaningful rebound into year-end.
|
Post a Comment
Post a Comment